Myogenin and MyoD1 Expression in Paediatric Rhabdomyosarcomas

Overview

Journal J Clin Pathol

Specialty Pathology

Date 2003 Jun 5

PMID 12783965

Citations 64

Authors

N J Sebire

M Malone

Affiliations

Soon will be listed here.

Abstract

The diagnosis of paediatric solid tumours is often based on small tissue needle biopsies in which many different entities demonstrate a "small round cell tumour" phenotype and in which there may be insufficient tissue to allow the interpretation of diagnostic architectural features, which may be present in larger specimens. Therefore, the extensive use of a panel of immunohistochemical markers is part of the routine handling and investigation of such biopsies to reach a definite diagnosis. However, in some cases the morphological and routine immunohistochemical findings may be insufficient for a precise diagnosis or they may be difficult to interpret in the given clinical context. Although many paediatric tumours exhibit characteristic chromosomal translocations with resultant specific fusion transcripts, these require molecular methods for their detection, usually on fresh tissue samples, which may not always be available. As more immunohistochemical markers become available, more precise diagnosis on such small biopsies may be possible. This review examines the use of the immunohistochemical markers, MyoD1 and myogenin, in the diagnosis of paediatric rhabdomyosarcoma, including its subtypes.

Citing Articles

Successful treatment of rare case of rhabdomyosarcoma of urinary bladder in adult, experience from tertiary hospital. Case report.

Chiloleti G, Lituli H, Sobbo S, Sensa V, Mushi F Int J Surg Case Rep. 2024; 123:110296.

PMID: 39293226 PMC: 11424959. DOI: 10.1016/j.ijscr.2024.110296.

Transcriptional activation of PINK1 by MyoD1 mediates mitochondrial homeostasis to induce renal calcification in pediatric nephrolithiasis.

Zhang K, Fang X, Zhang Y, Zhang Y, Chao M Cell Death Discov. 2024; 10(1):397.

PMID: 39242558 PMC: 11379875. DOI: 10.1038/s41420-024-02117-w.

We need to talk-how muscle stem cells communicate.

Majchrzak K, Hentschel E, Honzke K, Geithe C, von Maltzahn J Front Cell Dev Biol. 2024; 12:1378548.

PMID: 39050890 PMC: 11266305. DOI: 10.3389/fcell.2024.1378548.

MYOD-SKP2 axis boosts tumorigenesis in fusion negative rhabdomyosarcoma by preventing differentiation through p57 targeting.

Pomella S, Cassandri M, DArchivio L, Porrazzo A, Cossetti C, Phelps D Nat Commun. 2023; 14(1):8373.

PMID: 38102140 PMC: 10724275. DOI: 10.1038/s41467-023-44130-0.

The Association of Methylation Status and Expression Level of with Expression Level in Breast Cancer Patients.

Khojastehpour S, Foroughi F, Gheibi N, Mohammadi Z, Ahmadi M, Nasirian N Int J Hematol Oncol Stem Cell Res. 2023; 17(3):133-144.

PMID: 37817971 PMC: 10560649. DOI: 10.18502/ijhoscr.v17i3.13303.

References

Hosoi H, Sugimoto T, Hayashi Y, Inaba T, Horii Y, Morioka H . Differential expression of myogenic regulatory genes, MyoD1 and myogenin, in human rhabdomyosarcoma sublines. Int J Cancer. 1992; 50(6):977-83. DOI: 10.1002/ijc.2910500626. View

Cui S, Hano H, Harada T, Takai S, Masui F, Ushigome S . Evaluation of new monoclonal anti-MyoD1 and anti-myogenin antibodies for the diagnosis of rhabdomyosarcoma. Pathol Int. 1999; 49(1):62-8. DOI: 10.1046/j.1440-1827.1999.00825.x. View

Shapiro D, Valentine M, Sublett J, Sinclair A, Tereba A, Scheffer H . Chromosomal sublocalization of the 2;13 translocation breakpoint in alveolar rhabdomyosarcoma. Genes Chromosomes Cancer. 1992; 4(3):241-9. DOI: 10.1002/gcc.2870040309. View

Whang-Peng J, Knutsen T, Theil K, Horowitz M, Triche T . Cytogenetic studies in subgroups of rhabdomyosarcoma. Genes Chromosomes Cancer. 1992; 5(4):299-310. DOI: 10.1002/gcc.2870050405. View

Douglass E, Shapiro D, Valentine M, Rowe S, Carroll A, RANEY R . Alveolar rhabdomyosarcoma with the t(2;13): cytogenetic findings and clinicopathologic correlations. Med Pediatr Oncol. 1993; 21(2):83-7. DOI: 10.1002/mpo.2950210202. View

Barr F, Galili N, Holick J, Biegel J, Rovera G, Emanuel B . Rearrangement of the PAX3 paired box gene in the paediatric solid tumour alveolar rhabdomyosarcoma. Nat Genet. 1993; 3(2):113-7. DOI: 10.1038/ng0293-113. View

Hanaoka K, Hayasaka M, Esumi E, Li S, Nonaka I, Nabeshima Y . Myogenin gene disruption results in perinatal lethality because of severe muscle defect. Nature. 1993; 364(6437):532-5. DOI: 10.1038/364532a0. View

Faerman A, Pearson-White S, Emerson C, Shani M . Ectopic expression of MyoD1 in mice causes prenatal lethalities. Dev Dyn. 1993; 196(3):165-73. DOI: 10.1002/aja.1001960303. View

Shapiro D, Sublett J, Li B, Downing J, Naeve C . Fusion of PAX3 to a member of the forkhead family of transcription factors in human alveolar rhabdomyosarcoma. Cancer Res. 1993; 53(21):5108-12. View

10.

Galili N, Davis R, Fredericks W, Mukhopadhyay S, Rauscher 3rd F, Emanuel B . Fusion of a fork head domain gene to PAX3 in the solid tumour alveolar rhabdomyosarcoma. Nat Genet. 1993; 5(3):230-5. DOI: 10.1038/ng1193-230. View

11.

Davis R, DCruz C, Lovell M, Biegel J, Barr F . Fusion of PAX7 to FKHR by the variant t(1;13)(p36;q14) translocation in alveolar rhabdomyosarcoma. Cancer Res. 1994; 54(11):2869-72. View

12.

Aurade F, Pinset C, Chafey P, Gros F, Montarras D . Myf5, MyoD, myogenin and MRF4 myogenic derivatives of the embryonic mesenchymal cell line C3H10T1/2 exhibit the same adult muscle phenotype. Differentiation. 1994; 55(3):185-92. DOI: 10.1046/j.1432-0436.1994.5530185.x. View

13.

Fredericks W, Galili N, Mukhopadhyay S, Rovera G, Bennicelli J, Barr F . The PAX3-FKHR fusion protein created by the t(2;13) translocation in alveolar rhabdomyosarcomas is a more potent transcriptional activator than PAX3. Mol Cell Biol. 1995; 15(3):1522-35. PMC: 230376. DOI: 10.1128/MCB.15.3.1522. View

14.

Sublett J, Jeon I, Shapiro D . The alveolar rhabdomyosarcoma PAX3/FKHR fusion protein is a transcriptional activator. Oncogene. 1995; 11(3):545-52. View

15.

Pappo A, Shapiro D, Crist W, Maurer H . Biology and therapy of pediatric rhabdomyosarcoma. J Clin Oncol. 1995; 13(8):2123-39. DOI: 10.1200/JCO.1995.13.8.2123. View

16.

Bennicelli J, EDWARDS R, Barr F . Mechanism for transcriptional gain of function resulting from chromosomal translocation in alveolar rhabdomyosarcoma. Proc Natl Acad Sci U S A. 1996; 93(11):5455-9. PMC: 39267. DOI: 10.1073/pnas.93.11.5455. View

17.

Barr F, Nauta L, Davis R, Schafer B, Nycum L, Biegel J . In vivo amplification of the PAX3-FKHR and PAX7-FKHR fusion genes in alveolar rhabdomyosarcoma. Hum Mol Genet. 1996; 5(1):15-21. DOI: 10.1093/hmg/5.1.15. View

18.

Arden K, Anderson M, Finckenstein F, Czekay S, Cavenee W . Detection of the t(2;13) chromosomal translocation in alveolar rhabdomyosarcoma using the reverse transcriptase-polymerase chain reaction. Genes Chromosomes Cancer. 1996; 16(4):254-60. DOI: 10.1002/(SICI)1098-2264(199608)16:4<254::AID-GCC5>3.0.CO;2-X. View

19.

Khan J, Bittner M, Saal L, Teichmann U, Azorsa D, Gooden G . cDNA microarrays detect activation of a myogenic transcription program by the PAX3-FKHR fusion oncogene. Proc Natl Acad Sci U S A. 1999; 96(23):13264-9. PMC: 23936. DOI: 10.1073/pnas.96.23.13264. View

20.

Dias P, Chen B, Dilday B, Palmer H, Hosoi H, Singh S . Strong immunostaining for myogenin in rhabdomyosarcoma is significantly associated with tumors of the alveolar subclass. Am J Pathol. 2000; 156(2):399-408. PMC: 1850049. DOI: 10.1016/S0002-9440(10)64743-8. View